Anzeige
Mehr »
Login
Dienstag, 26.01.2021 Börsentäglich über 12.000 News von 653 internationalen Medien
Ausgezeichnet! East Africa Metals -Ausbruch und Rallye am Montag?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 913048 ISIN: FR0005175080 Ticker-Symbol: TGNA 
Frankfurt
25.01.21
19:45 Uhr
2,480 Euro
-0,015
-0,60 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRANSGENE SA Chart 1 Jahr
5-Tage-Chart
TRANSGENE SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,4852,53525.01.

Aktuelle News zur TRANSGENE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoFirst Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene's Innovative Individualized Immunotherapy186Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient...
► Artikel lesen
19.01.Transgene and BioInvent on go with study of BT-001 in solid tumors7
TRANSGENE Aktie jetzt für 0€ handeln
19.01.Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors162Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it has received approval...
► Artikel lesen
14.01.Transgene Appoints Gaëlle Stadtler as Director of Human Resources231Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the appointment of Gaëlle Stadtler...
► Artikel lesen
06.01.Report on the Transgene Liquidity Contract with Natixis Oddo BHF SCA as of December 31, 2020211Regulatory News: Under the liquidity contract between Transgene (Paris:TNG) and Natixis Oddo BHF SCA, on December 31, 2020, the resources provided for market making activities consisted of: ...
► Artikel lesen
21.12.20BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors245LUND, Sweden and STRASBOURG, France, Dec. 21, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel...
► Artikel lesen
21.12.20Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors206Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International...
► Artikel lesen
17.12.20Transgene Announces Financial Calendar for 2021179Regulatory News Transgene (Paris:TNG) today announced its financial reporting dates for 2021: March 10, 2021: 2020 Fiscal Year Results April 27, 2021: ...
► Artikel lesen
16.12.20Transgene Announces Investor Meetings for January 2021198Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below. Transgene will meet institutional...
► Artikel lesen
03.12.20Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in Advanced HPV-Positive Cancers at ESMO IO 2020329Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 trial results of TG4001, a HPV16...
► Artikel lesen
03.12.20Transgene Appoints Hedi Ben Brahim as Chairman and Chief Executive Officer175Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board, at its meeting today, approved the...
► Artikel lesen
09.11.20Transgene And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting214Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International...
► Artikel lesen
09.11.20Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers at SITC 2020168Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5% Presence of liver metastases had a notable impact on outcomes:...
► Artikel lesen
09.11.20BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting217LUND, Sweden and STRASBOURG, France, Nov. 9, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel...
► Artikel lesen
05.11.20Transgene provides Q3 update2
05.11.20Transgene Reports Business Update and End Q3 2020 Financial Position238Promising clinical data for TG4001 late breaker abstract at SITC 2020 Advanced technological leadership with the myvac platform: two clinical trials in patients with solid tumors initiated in January...
► Artikel lesen
05.11.20Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summit238'Viral Immunotherapy Meets AI Technology' Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment...
► Artikel lesen
27.10.20Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers281Combination of TG4001 and avelumab demonstrates anti-tumor activity (23.5% overall response rate (ORR)) in patients with previously treated recurrent and/or metastatic HPV-related cancers. ...
► Artikel lesen
19.10.20Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers241Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of the...
► Artikel lesen
15.10.20BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting360LUND, Sweden and STRASBOURG, France, Oct. 15, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel...
► Artikel lesen
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1